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Background: Recent data suggest that alterations in the neutrophil-to-lymphocyte ratio 
(NLR) in the perioperative periods can serve as prognostic factors. However, research on 
the clinical impact has been limited and even discordant in patients with colorectal cancer 
(CRC).
Patients and Methods: The optimal cut-off value of preoperative NLR (NLR-pre), post-
operative NLR (NLR-post), and its change (NLR-delta) were determined to maximize 
differences in overall survival (OS) between groups. Patients were categorized into four 
groups (NLR-trend) as follows: G1, low NLR-pre and NLR-post; G2, low NLR-pre and high 
NLR-post; G3, high NLR-pre and low NLR-post; and G4, high NLR-pre and NLR-post. 
Discriminatory performance was compared using integrated AUC (iAUC) between all 
indicators.
Results: A total of 576 patients diagnosed with stage I–IV CRC were included. The cut-off 
points were determined as 2.33 for NLR-pre, 2.06 for NLR-post, and −1.08 for NLR-delta. 
Subgroup dichotomization using NLR-pre, NLR-post, NLR-delta and NLR-trend were all 
identified as significant prognostic factors by univariate analysis. However, NLR-trend was 
only remained as an independent prognostic factor in the multivariate analysis. The iAUC of 
the NLR-trend was superior to that of NLR-pre (bootstrap iAUC mean difference=0.036; 
95% CI 0.013–0.073), NLR-post (bootstrap iAUC mean difference=0.045; 95% CI 0.019– 
0.081) and NLR-delta (bootstrap iAUC mean difference=0.061; 95% CI 0.025–0.104).
Conclusion: Risk stratification and combining of preoperative and postoperative NLR 
(NLR-trend) can improve prognostic discrimination compared with single measurements or 
simple changes in NLR in patients with CRC.
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Introduction
Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies, 
both world and in Korea.1,2 It is very important to predict the prognosis of patients 
prognosis in order to best implement adjuvant chemotherapy or radiotherapy. Although 
clinical, pathologic, and molecular parameters that can predict prognosis have been 
evaluated,3,4 convenient and inexpensive predictors of clinical outcome in CRC nature 
have not yet been clearly introduced.
Systemic inflammation has been shown to be associated with long-term 
survival outcomes in various type of cancer patients.5,6 The neutrophil-to- 
lymphocyte ratio (NLR) is one of the most measured and evaluated indicators 
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due to the advantage of being easy to obtain through 
routine blood test, with a relatively low cost. Previous 
studies investigating the usefulness of NLR analyzed its 
clinical impact using either a preoperative (NLR-pre) or 
postoperative NLR (NLR-post).7,8 Recently, it was 
argued that the combination of preoperative and post-
operative systemic inflammatory markers could be inde-
pendently associated with overall survival (OS) or 
recurrence-free survival.9,10 Similarly, some investiga-
tors have tried to consider sequential changes in NLR 
(NLR-post minus NLR-pre), which is known as the 
NLR-delta. NLR-delta has been demonstrated as an 
alternative prognostic factor in patients with non-small 
cell lung cancer, hepatocellular carcinoma, gastric can-
cer, and anaplastic thyroid cancer.11–16
However, there are still some discrepancies in the clinical 
significance of grouping the NLR-pre and NLP-post9,10 and 
the clinical significance of NLR-delta in patients with CRC 
also showed conflicting results.17,18 In addition, the signifi-
cance of combining pre- and post-operative NLR (NLR-trend) 
and NLR-delta has rarely been evaluated simultaneously, and 
it remains unclear whether there is a difference in the strength 
of association with survival between the two dynamic 
matrices.
When previous studies analyzed longitudinal NLR 
changes, preoperative NLR was usually measured within 
1 month prior to surgery. However, re-measuring periods of 
postoperative NLR differ from study to study, which makes 
it difficult to generalize the results. A recent study showed 
that the inflammatory indices measured between 3 and 8 
weeks after surgery are values measured in a state that 
minimizes inflammation related to surgery.10 This period 
also coincides with the recommended initiation time for 
receipt of chemotherapy after surgical resection in patients 
with CRC.19,20 Therefore, the NLR value measured over 3– 
8 week periods could have a clinical advantage in deciding 
the implementation of postoperative chemotherapy.
The aim of the present study was to investigate and com-
pare the clinical impact of trajectory change of NLR from 
preoperative NLR and postoperative NLR measured during 3 
to 8 weeks postoperative periods in patients with CRC.
Patients and Methods
Patients
This was a retrospective, single-institution study that 
included patients diagnosed with stage I to IV CRC who 
underwent surgery with curative-intent between 
January 2004 and April 2014 at Gangnam Severance 
Hospital, Yonsei University College of Medicine.
The inclusion criteria were as follows: (1) patients who 
underwent surgical resection of stage I–IV CRC, (2) no 
previous chemotherapy or radiation treatment before surgery, 
and (3) available neutrophil and lymphocyte counts both in 
the preoperative period within 31 days before surgery and 
postoperative periods between 21 and 56 days after surgery. 
The exclusion criteria were as follows: (1) insufficient data of 
stage, (2) histology other than adenocarcinoma such as neu-
roendocrine tumor, gastrointestinal stromal tumors, and other 
types of cancers, (3) appendiceal cancer or anal cancer, (4) 
hereditary nonpolyposis colorectal cancer or familial adeno-
matous polyposis associated cancers, (5) inflammatory 
bowel disease, (6) postoperative blood sample acquired 
after initiation of postoperative chemotherapy, and (7) post-
operative blood sample acquired before discharge date due to 
delayed hospitalization. According to our inclusion and 
exclusion criteria, 567 patients were included in this study 
(Supplementary Figure S1).
All procedures performed in studies involving human 
participants were in accordance with the ethical standards 
of the institutional and/or national research committee and 
with the 1964 Declaration of Helsinki and its later amend-
ments or comparable ethical standards. The institutional 
ethics committee of Gangnam Severance Hospital, Yonsei 
University College of Medicine approved this study, and 
the need for informed consent was waived because of its 
retrospective design.
Definition of NLR-Pre, NLR-Post, 
NLR-Delta, and NLR-Trend
Neutrophil and lymphocyte counts were measured using 
routine laboratory systems. NLR was calculated as the abso-
lute neutrophil count divided by the absolute lymphocyte 
count. Blood samples were obtained preoperatively within 
31 days prior to surgical resection and postoperatively 21–56 
days after surgery. NLR values measured at these time points 
were defined as NLR-pre and NLR-post, respectively. NLR- 
delta was defined as NLR-post minus NLR-pre. In addition, 
patients were allocated into the high or low NLR groups 
based on the cut-off values of NLR-pre and NLR-post, 
respectively. Using the subgroups defined in this way, 
patients were divided into four groups (NLR-trend) as fol-
lows: G1, low preoperative and low postoperative NLR; G2, 
low preoperative but high postoperative NLR; G3, high 
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preoperative but low postoperative NLR; G4, high preopera-
tive and high postoperative NLR.
Follow-Up of Patients
All patients were followed regularly every 3–6 months for the 
first 3 years and every 6 months thereafter. Follow-up exam-
inations routinely included physical examination and blood 
laboratory tests, including carcinoembryonic antigen (CEA) 
tests. In most patients, abdominopelvic computed tomography 
(CT) and/or chest CT were performed every 6 months. Other 
examinations, such as colonoscopy, pelvic magnetic resonance 
imaging, or 18F-fluorodeoxyglucose positron-emission tomo-
graphy, were performed at the physician’s discretion. Patients 
were followed until October 2019 or death of the patient. The 
median follow-up period was 89 months (interquartile range 
[IQR], 61–110 months).
Statistical Analysis
OS was defined as the time from the date of surgery to the date 
of death from any cause or date of the last follow-up. To 
analyze the hazard ratio (HR) and 95% confidence interval 
(CI) for factors associated with OS, a Cox proportional hazard 
model was used. Among factors related to OS, only variables 
found to be significant (p <0.01) in the univariate Cox regres-
sion analysis were included in the multivariate analysis.
The X-tile program was used to set the optimal cut-off 
values of NLR-pre, NLR-post, and NLR-delta for predict-
ing OS.21 Kaplan-Meier curves and Log rank tests were 
used to compare survival outcomes between the groups.
The predictive accuracy of the model during the follow-up 
period was measured using the integrated area under the curve 
(iAUC), which is a weighted mean of AUC over the follow-up 
period. Differences in accuracy between NLR-derived predic-
tive models were calculated using a bootstrapping method 
with resampling performed 1000 times. A higher iAUC indi-
cates a higher predictive accuracy for the model.
Statistical analysis was performed using R version 
3.6.3 (R-project, Institute for Statistics and Mathematics, 
Vienna, Austria). Statistical significance was set at p<0.05.
Results
A total of 567 patients were included in the study. The 
median age was 63 (IQR, 55–70) years; 342 (60.3%) were 
men and 225 (39.7%) were women. During the study 
period, 177 patients (31.2%) died. The median values of 
NLR-pre and NLR-post were 2.27 (IQR, 1.653–3.124) and 
1.832 (IQR, 1.347–2.472), respectively. The median value 
of NLR-delta was −0.427 (IQR, −1.164–0.228).
Optimal Cut-Off Values of NLR Related 
Parameters
The cut-off values of NLR-pre and NLR-post that showed 
the largest χ2 in the Mantel–Cox test were set as 2.33, and 
2.06, respectively. Patients were divided into low and high 
NLR groups according to the cut-off values. Among the 
567 patients, 273 (48.1%) and 219 (38.6%) patients were 
allocated to the high NLR group in the preoperative and 
postoperative periods, respectively. The optimal cut-off 
value of NLR-delta was also calculated in the same way, 
and was defined as −1.08 (Supplementary Figure S2).
Comparison of Patient Characteristics 
According to the Low and High NLRs
There were significant differences in sex and, preoperative 
CEA between the low NLR-pre and the high NLR-pre 
groups. No significant differences were found in age, body 
mass index (BMI), tumor location, histologic grade, lympho-
vascular invasion (LVI), complication, stage, or receipt of 
chemotherapy between the two groups. Conversely, for post-
operative NLR, there were significant differences in sex, age, 
histologic grade, and complications between the low NLR- 
post and high NLR-post groups (Table 1).
Kaplan-Meier Curves According to 
NLR-Pre, NLR-Post, NLR-Delta, and 
NLR-Trend
There was a significant difference in OS between the low 
and high NLR-pre groups (p<0.001) (Figure 1A). The 
5-year OS rate was significantly lower in the high NLR- 
post group than in the low NLR-post group (p=0.003) 
(Figure 1B). Significant differences were observed with 
regard to OS among the four groups defined as NLR- 
trend. Among the four groups, G1, which was defined as 
persistently low preoperative and postoperative NLRs, was 
significantly associated with better OS than the other 
groups (Figure 1C). The low NLR-delta group showed 
worse OS than the high NLR-delta group (Figure 1D).
Univariate and Multivariate Analysis of 
OS
Univariate Cox regression analysis found that sex (HR 1.59, 
95% CI 1.15–2.20, p=0.004), an age (HR 1.66, 95% CI 1.23– 
2.23, p=0.0008), CEA (HR 1.86, 95% CI 1.37–2.52, 
p<0.001), LVI (HR 2.09, 95% CI 1.52–2.87, p<0.001), 
stage IV (versus stage I&II, HR 5.23, 95% CI 3.54–7.73, 
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p<0.001), complications (HR 1.43, 95% CI 1.02–1.99, 
p=0.036), chemotherapy (HR 0.39, 95% CI 0.29–0.52, 
p<0.001), NLR-pre (HR 1.67, 95% CI 1.24–2.26, 
p=0.0007), NLR-post (HR 1.56, 95% CI 1.16–2.1, 
p=0.003), NLR-trend and NLR-delta (HR 0.68, 95% CI 
0.5–0.94, p=0.02) were significantly associated with OS 
(Table 2). Subsequent multivariate Cox regression identified 
LVI present vs absent (HR 1.45, 95% CI 1.04–2.04, 
p=0.027), stage [stage III vs stage I & II (HR 1.9, 95% CI 
1.23–2.94, p=0.003, stage IV vs stage I & II (HR 4.11, 95% 
CI 2.67–6.33, p<0.001)], chemotherapy (HR 0.37, 95% CI 
0.26–0.53, p<0.001), and NLR-trend as independent risk 
factors for OS (Table 2). The clinical significance of NLR- 
trend was confirmed in a subgroup analysis performed using 
stage II and stage III patients. (Supplementary Table 1).
Integrated AUC
Throughout the observation period, the integrated AUC value 
of NLR-trend (0.599, 95% CI=0.562–0.637) was superior to 
that of NLR-pre (0.562, 95% CI=0.524–0.599) (bootstrap 
iAUC mean difference=0.036, 95% CI=0.013–0.073), NLR- 
post (0.553, 95% CI=0.516–0.589) (bootstrap iAUC mean 
difference=0.045, 95% CI=0.019–0.081), and NLR-delta 
(0.537, 95% CI=0.504–0.570) (bootstrap iAUC mean differ-
ence=0.061, 95% CI=0.025–0.104), respectively (Figure 2).
Discussion
This study demonstrated that the combinational stratifica-
tion using trajectory change of NLR (NLR-trend) has 
superior prognostic performance than using NLR 
Table 1 Characteristics of Patients (n=567)
NLR-Pre p NLR-Post p
Low (n=294) N (%) High (n=273) N (%) Low (n=348) N (%) High (n=219) N (%)
Sex Female 134 (45.6) 91 (33.3) 0.004 150 (43.1) 75 (34.2) 0.044
Male 160 (54.4) 182 (66.7) 198 (56.9) 144 (65.8)
Age (years) < 65 170 (57.8) 139 (50.9) 0.117 212 (60.9) 97 (44.3) <0.001
≥ 65 124 (42.2) 134 (49.1) 136 (39.1) 122 (55.7)
BMI (kg/m2) < 25 205 (69.7) 196 (71.8) 0.828 234 (67.2) 167 (76.3) 0.066
≥ 25 86 (29.3) 75 (27.5) 111 (31.9) 50 (22.8)
No data 3 (1) 2 (0.7) 3 (0.9) 2 (0.9)
CEA (ng/mL) < 5 187 (63.6) 152 (55.7) 0.04 221 (63.5) 118 (53.9) 0.054
≥ 5 93 (31.6) 113 (41.4) 113 (32.5) 93 (42.5)
No data 14 (4.8) 8 (2.9) 14 (4) 8 (3.7)
Tumor location Colon 217 (73.8) 203 (74.4) 0.958 260 (74.7) 160 (73.1) 0.753
Rectum 77 (26.2) 70 (25.6) 88 (25.3) 59 (26.9)
Histologic grade G1 & G2 271 (92.2) 248 (90.8) 0.312 323 (92.8) 196 (89.5) 0.047
G3 12 (4.1) 8 (2.9) 7 (2) 14 (5.9)
Mucinous & SRC 11 (3.7) 17 (6.2) 18 (5.2) 10 (4.6)
LVI Absent 191 (65) 173 (63.4) 0.187 231 (66.4) 133 (60.7) 0.389
Present 81 (27.6) 88 (32.2) 97 (27.9) 72 (32.9)
No data 22 (7.5) 12 (4.4) 20 (5.7) 14 (6.4)
Complications No 233 (79.3) 211 (77.3) 0.642 287 (82.5) 157 (71.7) 0.003
Yes 61 (20.7) 62 (22.7) 61 (17.5) 62 (28.3)
AJCC Stage I  & II 118 (40.1) 93 (34.1) 0.293 133 (38.2) 78 (35.6)
0.461
III 131 (44.6) 130 (47.6) 162 (46.6) 99 (45.2)
IV 45 (15.3) 50 (18.3) 53 (15.2) 42 (19.2)
Chemotherapy No 93 (31.6) 72 (26.4) 0.199 101 (29) 64 (29.2) >0.99
Yes 201 (68.4) 201 (73.6) 247 (71) 155 (70.8)
NLR-delta Median (IQR) −0.01 (−0.42, 0.62) −1.19 (−1.97, −0.52) <0.001 −0.65 (−1.39, −0.15) 0.14 (−0.79, 0.95) <0.001
Abbreviations: BMI, body mass index; CEA, carcinoembryonic antigen; SRC, signet ring cell; LVI, lymphovascular invasion; AJCC, American Joint Committee on Cancer; 
HR, hazard ratio; CI, confidence interval.
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measured either in the preoperative or postoperative per-
iod, or the NLR-delta value in patients with CRC.
Among the various inflammatory markers, NLR is 
known as a serum biomarker useful in predicting 
prognosis.22 Neutrophils activate endothelial and parench-
ymal cells and generate various reactive oxygen species, 
causing DNA damage,23 as well as creating various med-
iators that promote cancer proliferation and metastasis. 
Lymphocytes are involved in anti-tumor activity and inhi-
bit tumor cell proliferation and migration.24 Lymphopenia 
can be a marker for depressed cell-mediated immunity.25 
Therefore, it is known that NLR could reflect the balance 
between the anticancer immune system and procancer 
inflammatory reaction.26
There are two distinct manners to consider the trajectory 
changes of preoperative and postoperative NLRs. One way 
was to calculate the NLR-delta, which was defined as “post-
operative NLR minus preoperative NLR”. It was reported 
that a postoperative increase in NLR (positive NLR-delta 
value) was associated with worse survival outcomes in most 
of the previous studies. With respect to CRC, however, 
there have been contradictory results regarding the associa-
tion between NLR-delta and prognosis. Guo et al showed 
that high NLR-delta was associated with worse OS (NLR- 
delta ≤0.037 vs >0.037, HR 0.315, 95% CI 0.107–0.930, 
p=0.037).17 In contrast, Li et al reported that increased 
NLR-delta was associated with better OS (NLR-delta ≥0 
vs <0, HR 0.223, 95% CI 0.093–0.534, p=0.001).18
The other way was to combine the two subgroups 
(NLR-trend) after dividing patients into low-and high- 
risk groups, according to the specific values of pre- and 
postoperative NLRs, respectively. Although recent studies 
have shown that the NLR-trend showed statistical signifi-
cance in predicting survival in patients with CRC, there 
was some discordance in survival differences among the 
subgroups. Chan and colleagues reported that the elevated 
group (low preoperative NLR changed to high postopera-
tive NLR) showed a significantly higher risk of death (HR 
Figure 1 Kaplan-Meier survival curve of neutrophil-to-lymphocyte ratio related parameters for overall survival of CRC patients. (A) NLR-pre; The low NLR-pre group 
(NLR-pre ≤2.33) had better OS compared to high NLR-pre group (NLR-pre >2.33) (5 year OS: 82.6% versus 70.5%; p<0.001). (B) NLR-post; The low NLR-post group 
(NLR-post ≤2.06) was associated with better OS compared to high NLR-post group (NLR-post >2.06) (5 year OS: 80.1% versus 71.4%; p=0.003). (C) NLR-trend; The G1 
(low NLR-pre and low NLR-post group) was significantly associated with better OS than the other groups (low NLR-pre and high NLR-post group, high NLR-pre and low 
NLR-post group and high NLR-pre) (5 year OS: 86.4%, 73.6%, 70.2% and 70.0% respectively, p=0.001). (D) NLR-delta; The low NLR-delta group (NLR-delta ≤-1.08) had 
worse OS compared to high NLR-delta group (NLR-delta >-1.08). (5 year OS: 69.5% versus 79.4%; p=0.003).
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2.156, 95% CI 1.453–3.199) than the persistently low 
NLR group using 587 stage I–IV CRC patients.10 
However, another study by Yasui and colleagues reported 
that the persistently low NLR group and exacerbation 
group (preoperative low to postoperative high NLR) 
showed no difference in survival in patients with stage 
III CRC.9
To the best of our knowledge, the prognostic impact of 
NLR-delta and NLR-trend has been investigated in 
a limited manner. Cui et al analyzed both NLR-delta and 
Table 2 Univariate and Multivariate Analysis of Factors Associated with Overall Survival (n=567)
Univariate Analysis Multivariate Analysis
HR (95% CI) p HR (95% CI) p
Sex Female Ref. Ref.
Male 1.59 (1.15–2.20) 0.004 1.37 (0.98–1.92) 0.06
Age (years) < 65 Ref. Ref.
≥ 65 1.66 (1.23–2.23) 0.0008 1.29 (0.94–1.77) 0.107
BMI (kg/m2) < 25 Ref. NA
≥ 25 0.70 (0.49–1.00) 0.053 NA
No data 0.45 (0.06–3.25) 0.431 NA
CEA (ng/mL) < 5 Ref. Ref.
≥ 5 1.86 (1.37–2.52) <0.001 1.33 (0.96–1.85) 0.08
No data 0.90 (0.36–2.21) 0.81 0.67 (0.26–1.68) 0.39
Tumor site Colon Ref.
Rectum 0.81 (0.57–1.15) 0.259
Histologic grade G1 & G2 Ref.
G3 1.60 (0.78–3.26) 0.192
Mucinous & SRC 1.38 (0.75–2.54) 0.299
LVI Absent Ref. Ref.
Present 2.09 (1.52–2.87) <0.001 1.45 (1.04–2.04) 0.027
No data 2.29 (1.37–3.82) 0.001 2.00 (1.16–3.44) 0.012
AJCC Stage I  & II Ref. Ref.
III 1.35 (0.93–1.96) 0.109 1.90 (1.23–2.94) 0.003
IV 5.23 (3.54–7.73) <0.001 4.11 (2.67–6.33) <0.001
Complications No Ref. NA
Yes 1.43 (1.02–1.99) 0.036 NA
Chemotherapy No Ref. Ref.
Yes 0.39 (0.29–0.52) <0.001 0.37 (0.26–0.53) <0.001
NLR-pre Low Ref. NA
High 1.67 (1.24–2.26) 0.0007 NA
NLR-post Low Ref. NA
High 1.56 (1.16–2.10) 0.003 NA
NLR-trend G1 Ref. Ref.
G2 2.18 (1.38–3.46) 0.0008 1.86 (1.17–2.97) 0.0084
G3 2.15 (1.43–3.23) 0.0002 2.02 (1.33–3.08) 0.0009
G4 2.28 (1.50–3.46) 0.0001 2.00 (1.30–3.10) 0.0016
NLR-delta Low Ref. NA
High 0.68 (0.5–0.94) 0.02 NA
Abbreviations: BMI, body mass index; CEA, carcinoembryonic antigen; SRC, signet ring cell; LVI, lymphovascular invasion; AJCC, American Joint Committee on Cancer; 
HR, hazard ratio; CI, confidence interval.
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Figure 2 Predictive accuracy of the model during follow-up period was measured using the iAUC, a weighted mean of AUC over follow-up period. The time-dependent 
receiver operating characteristics curve of the NLR-trend was superior to that of NLR-pre (A) (bootstrap iAUC mean difference = 0.036; 95% CI 0.013–0.073), NLR-post 
(B) (bootstrap iAUC mean difference = 0.045; 95% CI 0.019–0.081) (B) and NLR-delta (C) (bootstrap iAUC mean difference = 0.061; 95% CI 0.025–0.104).
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NLR groupings to determine the association with progres-
sion-free survival (PFS) and reported that NLR-delta could 
not predict PFS, while grouping low-low and low-high 
subgroups had better PFS.27 Nevertheless, the time point 
for postoperative NLR measurement in that study was 
described as at least 7 days after the surgery, which was 
too broad to be a standard.
In this context, the strength of our study is that the 
different NLR-related parameters were included simulta-
neously, and the discriminatory performance was statistically 
compared using iAUC. We set the optimal cut-off value of 
NLR-delta as −1.08; however, this dichotomy was not asso-
ciated with survival in the multivariate analysis. With respect 
to NLR-trend, our analysis showed that G2 (low NLR-pre 
and high NLR-post) showed a significantly higher risk of 
death (HR 1.86, 95% CI 1.17–2.97, p=0.0084) than G1, in 
concordance with the results of Chan et al. These results 
indicate that the elevated NLR group in both perioperative 
periods showed poor survival outcomes compared with the 
persistently low NLR group. This agrees with our previous 
analysis in patients with locally advanced rectal cancer, 
which demonstrated that a persistently low NLR during pre-
operative chemoradiotherapy treatment was associated with 
better disease-free survival than the other groups (HR 0.37, 
95% CI 0.15–0.89, p=0.033).28 In addition, we found that the 
NLR-trend showed better discriminatory performance than 
the other NLR-related parameters such as NLR-pre, NLR- 
post and NLR-delta.
Another value of our study is that the timing of post-
operative NLR measurement was clearly defined. Previous 
studies did not mention the timing of postoperative NLR 
tests, nor did they examine the immediate postoperative 
periods, 1–4 months or 3–6 months after surgery 
(Supplementary Tables 2 & 3). In our study, we strictly 
selected patients whose postoperative NLR test was per-
formed between 21–56 days postoperatively, before start-
ing postoperative chemotherapy. This time point is thought 
to be an appropriate time to measure the patient’s intrinsic 
NLR level, in which the effect of surgery-induced NLR 
rise disappears and the effect of the start of chemotherapy 
is not involved.10 A meta-analysis of 14 studies showed 
that a delay of >8 weeks in starting adjuvant chemotherapy 
is associated with a higher relative risk of death (HR 1.20, 
95% CI 1.15–1.26, p=0.001).29 Thus, starting chemother-
apy within 8 weeks after surgery is highly recommended 
in the guidelines.20,29 If it is possible to make a decision 
on the implementation of chemotherapy by comparing the 
NLR measured pre- and postoperatively, it would provide 
great help for the patients. In our study, the group with 
consistently low NLR before and after surgery showed the 
best prognosis. In view of results of our study, in order to 
use NLR as a clinical indicator, both preoperative and 
postoperative NLR should be considered together. The 
inflammatory reaction after the surgery derived from post-
operative complications or residual tumor burden can 
effects the prognosis even in patients with low preopera-
tive NLR. This observation may be clinically useful in 
decision making regarding whether a patient with CRC 
who underwent surgical resection can omit postoperative 
chemotherapy, although further investigation is required to 
confirm our hypothesis.
Our study has several limitations. Firstly, it was 
a retrospective single-center study, meaning selection 
bias is inevitable. There is no consensus on the cut-off 
values of NLR-related parameters, and therefore the opti-
mized values for our cohort were selected. This might 
hinder the generalized application of our results. 
However, if we wish to apply a predefined NLR threshold, 
the clinical significance of NLR should be the same, which 
would be quite difficult to assume considering different 
patient or disease characteristics.30 During postoperative 
periods, NLR can be elevated due to various causes. One 
cause of this could be systemic inflammation due to post-
operative complications. In our study, as mentioned earlier, 
to minimize the effect of surgery itself on the postopera-
tive NLR value, the time point of postoperative laboratory 
sampling was highly specified. In this context, to prevent 
bias caused by neutrophil elevation due to postoperative 
complications, our study excluded patients whose dis-
charge date was later than the date that the postoperative 
NLR results were collected. In some aspects, these 
excluded patients may have a worse prognosis, which 
could cause another selection bias.
In conclusion, our study revealed that combining pre-
operative and postoperative NLR acts synergistically to 
improve prognostic accuracy compared with preoperative, 
postoperative alone, or NLR-delta, and patients with per-
sistently low NLR values through perioperative periods 
showed the best prognosis. Considering the recommended 
period of post-operative chemotherapy, the clinical impli-
cation of stratification as a suitable indicator for adding 
adjuvant chemotherapy and a guide to patient-specific 
therapeutic interventions need to be investigated.
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